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Abstract
African sleeping sickness is a debilitating and often fatal disease caused by tsetse fly transmitted African trypanosomes.
These extracellular protozoan parasites survive in the human bloodstream by virtue of a dense cell surface coat made of
variant surface glycoprotein. The parasites have a repertoire of several hundred immunologically distinct variant surface
glycoproteins and they evade the host immune response by antigenic variation. All variant surface glycoproteins are
anchored to the plasma membrane via glycosylphosphatidylinositol membrane anchors and compounds that inhibit the
assembly or transfer of these anchors could have trypanocidal potential. This article compares glycosylphosphatidylinositol
biosynthesis in African trypanosomes and mammalian cells and identifies several steps that could be targets for the
development of parasite-specific therapeutic agents. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sleeping sickness a¡ects millions of people in sub-
Saharan Africa and the WHO estimates that there
are currently over 300 000 new cases a year. There
are no vaccines and current drugs are relatively toxic
and di⁄cult to administer. The African trypano-
somes are extracellular protozoan parasites that live
in the blood, lymph and interstitial £uids of the in-
fected mammalian host where they divide by binary
¢ssion. The ability of the trypanosome population to
evade the host immune response is due to a dense
and uniform protective coat [1] made of about 107
copies/cell of a 55 kDa variant surface glycoprotein
(VSG) [2] (Fig. 1). This dense palisade of VSG gly-
coprotein forms a di¡usion barrier that prevents the
approach of macromolecules to the parasite plasma
membrane and protects the parasite from lysis by the
alternative- and lectin-mediated complement path-
ways. An individual trypanosome expresses only
one VSG gene at a time but contains about a thou-
sand VSG genes encoding structurally similar [3] but
immunologically distinct VSGs. In natural and ex-
perimental infections, the mammalian host mounts
a potent humoral immune response to the prevailing
population of VSG coats that leads to almost com-
plete clearance of the parasites. However, the switch-
ing of VSG genes by some parasites gives rise to a
new population that replicates unchecked until an-
other speci¢c immune response is elicited. This proc-
ess of antigenic variation [4] is repeated until the
death of the host.
Depending on the VSG variant, VSG monomers
contain one, two or three N-glycosylation sites occu-
pied by oligomannose and/or complex oligosaccha-
rides [5^7]. All VSGs form homodimers anchored to
the plasma membrane via glycosylphosphatidylinosi-
tol (GPI) membrane anchors (one per VSG mono-
mer) of conserved structure that vary only in the
extent of their side chain galactosylation [7]. In con-
trast to the extremely high density of GPI-anchored
glycoproteins in the trypanosome (Fig. 1), mamma-
lian cells contain mostly transmembrane and periph-
eral glycoproteins at the cell surface and GPI-an-
chored proteins are in the minority. To put this into
context, one of the most abundant mammalian GPI-
anchored proteins is rat thymocyte Thy-1 (present at
about 6U105 copies per cell [8]) and a piece of mem-
brane like that modelled (Fig. 1) for the trypanosome
would contain less than one molecule of Thy-1. De-
spite their lower density, mammalian GPI-anchored
proteins are clearly vital since GPI knockouts are
embryo-lethal in mice and tissue-speci¢c GPI knock-
out causes signi¢cant tissue-speci¢c defects [9].
In conclusion, the absolute dependence of the tryp-
anosome on its protective VSG coat, and the de-
pendence of the latter on its GPI anchors, makes
the parasite GPI biosynthetic pathway an attractive
therapeutic target. However, the presence, and im-
portance, of GPI anchored glycoproteins in mam-
mals suggest that parasite-speci¢c inhibitors of GPI
biosynthetic enzymes are desirable. This article fo-
cuses on the known and suggested di¡erences be-




4GlcNK1-6myo-inositol1-P-lipid core region of all
protein-linked GPI membrane anchors [10^45] (Fig.
2) suggests conservation in the GPI biosynthetic ma-
chinery. The African trypanosome played a key role
in the development of methodologies to study GPI
biosynthesis. Intact GPI anchor precursors were ¢rst
identi¢ed and characterised in T. brucei [46^48] and
it was used to develop the ¢rst cell-free system to
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delineate the GPI biosynthetic pathway [49]. The
cell-free system is based on washed membranes
primed with UDP-GlcNAc and GDP-[3H]Man in
the presence of tunicamycin to suppress the synthesis
of dolichol cycle intermediates. The radiolabelled
GPI intermediates formed in the membranes from
endogenous phosphatidylinositol (PI) are extracted
in solvent and analysed by thin-layer chromatogra-
phy. Enzyme and chemical treatments are then used
to assign the chemical structures of the GPI inter-
mediates. This system has been adapted to study
GPI biosynthesis in a variety of organisms, includ-
ing mammalian cells and yeast ([50^54], and referen-
ces therein). The essential features of GPI biosyn-
thesis in the bloodstream form of T. brucei [49,55]
and mammalian cells [50,51] are shown in Fig.
3A,B.
2.1. The UDP-GlcNAc:PI K1-6
N-acetylglucosaminyltransferase complex
The biosynthesis of GPI anchors starts with the
transfer of GlcNAc from UDP-GlcNAc to PI
[56,57] on the cytoplasmic face of the ER [58,59].
In mammalian cells, this simple reaction requires at
least four proteins (PIG-A, PIG-C, PIG-H and
hGPI-1) that form a complex in the ER membrane
(Fig. 3C) [60,61]. The PIG-A component is most
likely the catalytic subunit since it has homology
with a bacterial GlcNAc-transferase. Homologues
of the PIG-A, PIG-C and hGPI-1 genes (GPI3,
GPI2 and GPI1, respectively) exist in the yeast Sac-
charomyces cerevisiae [62^64] but a PIG-H homo-
logue is missing in that organism.
There is relatively little information on the specif-
Fig. 1. T. brucei, the VSG coat and the VSG GPI membrane anchor. A scanning electron micrograph (courtesy of M. Duszenko) of
a bloodstream form T. brucei trypomastigote (top left) is shown next to a cartoon model (top right) of a 20 nmU20 nm section of
the plasma membrane [7]. The structure of a VSG dimer, based on the N-terminal crystal structure [3], is shown (bottom right) next
to the primary structure of the GPI anchor [11] (bottom left). The boxed section of the GPI anchor structure is conserved throughout
the eukaryotes. The galactose side chains and the fatty acids of the PI moiety, both myristate, are unique to VSG.
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Fig. 2. GPI anchor structures. All GPI anchors attached to protein contain the conserved structure shown above with various sub-
stituents (R1^R7) and lipids, as indicated. Some structures contain an additional fatty acyl chain attached to the 2-position of the
myo-inositol ring. All metazoan organisms contain at least one, and sometimes two, extra ethanolamine phosphate (EtNP) substituents
in addition to the one used as a bridge to the protein C-terminal amino acid. When a substituent is known to be attached to a certain
sugar residue but the linkage position is unknown, this is indicated by a question mark. Square brackets are used to show substituents
for which the site of attachment has not been determined. The þ symbol indicates that the associated residue is found on only a pro-
portion of the structures. AEP is 2-aminoethylphosphonate.
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icity of the GlcNAc-transferase complex, except that
(i) the partially puri¢ed mammalian complex prefers
bovine PI (i.e. primarily sn-1-stearoyl(C18:0)-2-arach-
idonoyl(C20:4)-PI) to soybean PI (i.e. primarily sn-1-
palmitoyl(C16:0)-2-linoleoyl(C18:2)-PI) and to lyso bo-
vine PI (i.e. primarily sn-1-stearoyl-2-lyso-PI) [61]
and (ii) the T. brucei enzyme can be inhibited by
sulphydryl alkylating agents. The latter inhibition
can be blocked by UDP-GlcNAc, suggesting that
the key cysteine residue is at, or close to, the sugar
donor binding site [65]. There is no information on
any of the GlcNAc-transferase components, or the
genes encoding them, in T. brucei.
2.2. The GlcNAc-PI de-N-acetylase
The GlcNAcK1-6PI intermediate is de-N-acetyl-
ated to produce GlcN-PI [56,57] and this step is a
prerequisite for further processing [66,67]. Rat
GlcNAc-PI de-N-acetylase gene has been cloned re-
cently, by complementation of the PIG-L mutant
CHO cells, and yeast and human homologues have
been identi¢ed [68]. The mammalian de-N-acetylase
does not appear to form a complex with the
GlcNAc-transferase complex [68] but it is not known
whether it associates with other components of the
GPI pathway. On the other hand, there is some evi-
dence for substrate channelling between this enzyme
and the ¢rst mannosyltransferase in T. brucei [66],
suggesting that the parasite de-N-acetylase and the
mannosyltransferases may form a complex.
The GlcNAc-PI de-N-acetylase of T. brucei has
been partially puri¢ed and characterised [69] using
a series of GlcNAc-PI analogues [70]. That study
concluded that: (i) the fatty acid esters assist in the
presentation of the GlcNAc-PI substrate to the en-
zyme, but are not essential for substrate recognition,
(ii) a phosphodiester linkage between the myo-inosi-
tol and glycerol residues is essential for substrate
recognition, (iii) product inhibition by GlcN-PI and
acetate is negligible and (iv) D-myo-inositol can be
replaced by L-myo-inositol without loss of substrate
recognition. Another study examined the substrate
speci¢cities of T. brucei and human (HeLa cell)
GlcNAc-PI de-N-acetylases with respect to the size
of the N-acyl (R) group that can be cleaved from a
series of GlcNR-PI substrates and the ability of these
enzymes to de-N-acetylate mannosylated GlcNAc-PI
intermediates [67]. It was concluded that: (i) the
trypanosomal and human enzymes are active on
GlcNR-PI substrates where R is acetyl or propionyl
but much less active on substrates where R is butyr-
yl, isobutyryl, pentanoyl or hexanoyl and (ii) man-
nosylated GlcNAc-PI structures are not substrates
for the trypanosomal or human de-N-acetylases,
demonstrating that de-N-acetylation must precede
mannosylation in GPI biosynthesis. A further study
examined the abilities of the human and parasite
enzymes to act on substrates with O-alkyl substitu-
ents attached to position 2 of the D-myo-inositol res-
idue and their stereospeci¢cities towards the myo-in-
ositol residue [71]. The results showed that the
human enzyme is more fastidious than the parasite
enzyme on both counts. Thus, whereas the trypano-
somal enzyme turned over all three of the substrate
analogues investigated (i.e. GlcNAc-(2-O-methyl)PI,
GlcNAc-(2-O-octyl)PI and GlcNAc-P(L)I), albeit at
lower rates than for GlcNAc-PI, the human enzyme
acted only on GlcNAc-(2-O-methyl)PI at a detect-
able rate. These di¡erences in the substrate speci¢c-
ities of the trypanosomal and human GlcNAc-PI de-
N-acetylases suggest that it may be possible to design
or discover parasite-speci¢c de-N-acetylase inhibitors
with therapeutic potential.
2.3. The Dol-P-Man:GlcN-PI/GlcN-(acyl)PI K1-4
mannosyltransferase (MT-I)
One major di¡erence between the parasite and
mammalian pathways is the relative order of inositol
acylation and mannosylation of GlcN-PI. T. brucei
strictly mannosylates GlcN-PI to Man1GlcN-PI pri-
or to inositol acylation [55,72] whereas the reverse is
true for the mammalian pathway [57,72,73] (see Fig.
3A,B and Fig. 4). The Dol-P-Man donor require-
ment of the ¢rst mannosyltransferase (MT-I), and
the subsequent mannosyltransferases, has been dem-
onstrated in T. brucei [74] but none of the proteins or
genes associated with the ¢rst or second mannosyla-
tion reactions have been identi¢ed in any organism.
The apparent di¡erence in the substrate speci¢city
of the parasite and host MT-I enzymes, requiring
GlcN-PI and GlcN-(acyl)PI as acceptor substrates,
respectively (Fig. 4), has been investigated using
cell-free systems and a series of synthetic GlcN-PI
analogues with O-alkyl substituents attached to posi-
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tion 2 of the D-myo-inositol residue. The ¢rst of
these, GlcN-(2-O-methyl)PI [75], was shown to be a
good substrate for T. brucei MT-I but neither a sub-
strate nor an inhibitor of HeLa cell MT-I [72]. The
identi¢cation of a selective substrate for T. brucei
MT-I suggested that parasite-speci¢c inhibitors
should also be attainable. This prediction was con-
¢rmed recently when GlcN-(2-O-octyl)PI and GlcN-
(2-O-hexadecyl)PI were tested and found to be para-
site-speci¢c GPI pathway inhibitors with di¡erent
modes of action: GlcN-(2-O-hexadecyl)PI inhibits
T. brucei MT-I while GlcN-(2-O-octyl)PI inhibits
the T. brucei inositol acyltransferase [76] (Fig. 4).
Although these compounds are unlikely to work in
vivo, since they will probably not pass through the
plasma membrane, the existence of parasite-speci¢c
inhibitors that are active in vitro is encouraging and
features of these compounds are being combined
with other information on the ¢ne speci¢city of T.
brucei MT-I [66] to design smaller and less polar
inhibitors.
2.4. Inositol acyltransferases and inositol deacylases
The role of inositol acylation (i.e., the esteri¢cation
of the hydroxyl group at the 2-position of the D-myo-
inositol residue with a fatty acid, most often palmitic
acid [41,77^79] (Fig. 2)) in GPI biosynthesis is largely
unknown. It is not an essential step in all organisms
since, for example, the Leishmania do not appear to
perform this reaction [80,81]. Furthermore, in many
cases (Fig. 2) the ¢nal protein-linked GPI anchor is
not inositol acylated. Nevertheless, in mammalian
cells and in yeast, most of the GPI intermediates
are inositol acylated [50^54] and in many mammali-
an cells, and in yeast, the fatty acid is removed from
the inositol residue immediately after transfer of the
mature GPI precursor to protein in the ER [82,83].
The timing, nature and role of inositol acylation
and inositol deacylation in T. brucei appears to be
quite unique. Thus, as noted above, whereas inositol
acylation of GlcN-PI precedes mannosylation in
mammalian cells [57,72,73] and in yeast [52] it only
occurs after the action of MT-I in T. brucei [55,72].
Furthermore, (i) inositol acylation is CoA and/or
acyl-CoA dependent in mammalian cells [73,84] and
yeast [52], but independent of these cofactors in T.
brucei [49,55]; (ii) inositol acylation is inhibited by
phenylmethylsulphonyl £uoride (PMSF) in T. brucei,
but not in mammalian cells [85]; (iii) the fatty acids
transferred to inositol are more heterogeneous in T.
brucei than they are in mammalian cells [86] and (iv)
most of the GPI intermediates in bloodstream forms
of T. brucei are in a dynamic equilibrium between
inositol acylated and inositol deacylated forms (Fig.
3A) via the actions of a PMSF-sensitive inositol acyl-
transferase [85] and a diisopropyl£uorophosphate
(DFP)-sensitive inositol deacylase [55]. The ability
to manipulate the acylation status of GPI intermedi-
ates in T. brucei with PMSF and DFP has shown
that, in that organism, inositol acylation is necessary
for e⁄cient addition of the ethanolamine phosphate
bridge and that subsequent inositol deacylation is
essential for the fatty acid remodelling reactions
[55,85] (see Fig. 3A). The former point was con-
¢rmed in the study with GlcN-(2-O-methyl)PI which
was e⁄ciently converted to Man3GlcN-(2-O-methyl)-
PI by the cell-free system but which failed to receive
the ethanolamine phosphate bridge [72]. Given the
importance of GPI fatty acid remodelling for T. bru-
cei (see below) and the essential nature of the etha-
nolamine phosphate bridge for GPI addition to pro-
tein, both the T. brucei inositol acyltransferase and
the inositol deacylase are potential therapeutic tar-
gets.
2.5. The Dol-P-Man:Man1GlcN-( þ acyl)PI K1-6
mannosyltransferase (MT-II)
Essentially nothing is known about the proteins or
6
Fig. 3. GPI biosynthesis in T. brucei bloodstream forms and mammalian cells. The general schemes of GPI biosynthesis in T. brucei
(A) and HeLa cells (B) are adapted from [55], and references therein, and [50,51], and references therein. The di¡erences in the order
of mannosylation by the ¢rst K-mannosyltransferase (MT-I) and inositol acylation by inositol acyltransferase (Acyl-T) and the di¡er-
ence in the timing of inositol deacylation by inositol deacylase (Ino de-Ac) are highlighted. Other signi¢cant di¡erences include the ad-
dition of an extra ethanolamine phosphate group to the ¢rst Man residue in the mammalian pathway and the nature of the side chain
carbohydrate modi¢cations that occur after GPI addition to protein. The topology [58,59] and known complexation, see text, of the
components of the mammalian GPI biosynthetic pathway are summarised in C.
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genes involved in this step of the pathway in any
organism.
2.6. The Dol-P-Man:Man2GlcN-( þ acyl)PI K1-2
mannosyltransferase (MT-III)
A gene (PIG-B) encoding a protein with homology
to a yeast K-mannosyltransferase was cloned [87] by
complementation of a murine thymoma mutant de-
¢cient in adding the third KMan residue to GPI in-
termediates [51]. The PIG-B gene is believed to en-
code MT-III and a yeast homologue (GPI10) has
been identi¢ed and shown to be essential for GPI
biosynthesis in yeast [53,54]. Expression of human
PIG-B cDNA rescued a GPI103 conditional mutant
under non-permissive conditions and restored GPI
biosynthesis, showing that the two genes are func-
tional homologues [54]. BLAST searches have also
revealed a T. brucei PIG-B homologue but there
are no functional data on this gene. The PIG-B
gene product is predicted to span the ER membrane
seven or nine times, which is a similar topology to
other ER resident glycosyltransferases [88] and di¡er-
ent from the type-2 membrane protein structure typ-
ical of Golgi glycosyltransferases.
MT-III activity has been detected in the T. brucei
cell-free system using the simple glycoside ManK1-
6ManK1-O-(CH2)7CH3 as an exogenous acceptor
[89] and the mechanism of the inhibition of GPI
biosynthesis by mannosamine [90,91] has been
studied in that organism [92]. Essentially, mannos-
amine is incorporated in GDP-Man and Dol-P-
Man and then into GPI intermediates to produce
ManNH2ManGlcN-PI. The latter has an amino
group in place of the hydroxyl acceptor site for
MT-III, and therefore cannot act as an acceptor,
and appears to inhibit the action of MT-III on en-
dogenous Man2GlcN-PI intermediates [92]. Unfortu-
nately, the e¡ects of mannosamine are not speci¢c to
trypanosomes and, because trypanosomes synthesise
an excess of GPI precursors [92,93], the addition of
GPI anchors to VSG is not prevented by mannos-
amine.
2.7. Ethanolamine phosphotransferases
All GPI anchors utilise an ethanolamine phos-
phate (EtNP) bridge between the third Man residue
and the COOH-terminal amino acid of the GPI-
anchored protein (except for a small proportion of
Trypanosoma cruzi anchors that utilise the EtNP
analogue 2-aminoethylphosphonate [20]). The origin
of this EtNP group has been shown to be the phos-
pholipid phosphatidylethanolamine (PE) in yeast [94]
and in T. brucei [95]. A mammalian gene (PIG-F)
required for the addition of the EtNP bridge has
been cloned by complementation but it is not known
whether this encodes the transferase itself or an es-
sential accessory element [96].
T. brucei, and many other protozoan organisms
such as Leishmania and Plasmodium falciparum, do
not express additional EtNP groups on the ¢rst and
second Man residues of the conserved GPI core. In
contrast, many other organisms express EtNP on the
¢rst Man residue and on some proportion of the
second Man residue (Fig. 2). It has recently come
to light that these additional EtNP groups are also
added during GPI biosynthesis in yeast [53,54]. This
has stimulated a reinterpretation [54] of the activity
of the terpenoid lactone compound YW3548, a po-
tent inhibitor of GPI biosynthesis in mammalian
cells and yeast but not in P. falciparum or T. brucei
[97]. Thus, it is possible that the accumulation of
Man2GlcN-(acyl)PI in yeast treated with YW3548
is due to the inhibition of EtNP addition to the ¢rst
Man residue rather than direct inhibition of MT-III.
This model assumes that yeast and mammalian MT-
III require the presence of the EtNP group on the
¢rst Man residue for substrate recognition [54]
whereas T. brucei MT-III does not; a di¡erence
6
Fig. 4. Di¡erences in the substrates and inhibitors of T. brucei and human GPI de-N-acetylases, mannosyltransferases and inositol
acyltransferases. The alternative routes from GlcNAc-PI to Man1GlcN-(acyl)PI taken by the T. brucei and mammalian (e.g. human
HeLa cell) and yeast GPI biosynthetic pathways are indicated at the top. The abilities of synthetic GlcN-PI, and analogues thereof, to
act as substrates (S) or inhibitors (I) of T. brucei and HeLa cell de-N-acetylase, MT-I and inositol acyltransferase are shown at the
bottom. Compounds that are neither substrates nor inhibitors are indicated by 3. *The de-N-acetylase results refer to the N-acetyl de-
rivatives of the compounds shown.
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that may be exploitable for the inhibition of trypa-
nosome MT-III. In any case, the selective inhibition
of GPI biosynthesis in yeast and mammalian cells by
YW3548 [97] is another indication of fundamental
di¡erences between parasite and mammalian/yeast
GPI biosynthesis.
2.8. Other GPI glycosyltransferases
The presence of additional Man residues in GPI
anchors is quite common (Fig. 2). In yeast, a fourth
Man residue is added to the GPI precursor before
transfer to protein [82] and the ¢fth Man residue
(that can be either K1-2 or K1-3 linked) is added in
the Golgi apparatus [98]. The origin of the fourth
Man residue in mammalian cells is less clear and it
may be added before or after GPI transfer to the
protein. The signi¢cance of the additional Man res-
idues is yet to be reported. Additional carbohydrate
side chains are quite common in mammalian cells,
e.g. the addition of GalNAc and/or GalL1-3GalNAc
in L1-4 linkage to the ¢rst Man residue (Fig. 2).
There is no information on the glycosyltransferases
responsible for these modi¢cations.
The GPI anchors on T. brucei VSG can be modi-
¢ed with several Gal residues (Figs. 1 and 2). The
proteins and genes responsible for these modi¢ca-
tions have not been identi¢ed but the activities of
two of them, the UDP-Gal:Man3GlcN-PI K1-3 ga-
lactosyltransferase [99,100] and the UDP-Gal:
Gal1Man3GlcN-PI K1-2 galactosyltransferase [101],
can be detected using the exogenous glycoside sub-
strates ManK1-2ManK1-S-(CH2)7CH3 and ManK1-
2(GalK1-3)ManK1-O-(CH2)7CH3, respectively. The
K- and L-galactosyltransferases that add Gal residues
directly to the trimannosyl core appear to be located
in the ER [11,102] while the others are most likely in
the Golgi apparatus [11,103].
The VSGs can be classi¢ed into four classes based
on COOH-terminal sequence homology [104]. Most
VSG variants belong to class-1 and class-2 and only
one class-4 variant and two class-3 variants are
known. The mean Gal content of the GPI glycans
of class-1 VSGs is 3.1 residues per mol GPI [10]
whereas this ¢gure is about 4.9 residues per mol
for the class-2 VSG [11] and the class-3 VSGs do
not contain any Gal [105]. These di¡erences in GPI
anchor galactosylation appear to re£ect steric con-
straints imposed by the VSG COOH-terminal struc-
ture on galactosyltransferase activity. This conclu-
sion is consistent with the original suggestion [106]
that GPI anchor galactosylation, that is unique to
African trypanosomes, is a mechanism for ¢lling
space close to the plasma membrane beneath and
around the VSG COOH-terminus. This processing
may be important in maintaining a functional pro-
tective barrier on the surface of the parasite regard-
less of which VSG variant is being expressed. Since
the GPI-modifying galactosyltransferases are unique
to the African trypanosomes, and since the repertoire
of non-galactosylated class-3 VSG variants is so
small, these enzymes could be considered potential
therapeutic targets.
2.9. GPI lipid remodelling
Lipid exchange occurs in yeast where diacylglycer-
ol is exchanged for ceramide in the ER and where
this ceramide can be exchanged for another ceramide
in the Golgi [82,107,108]. Furthermore, the presence
of exclusively distearoyl-PI in some mammalian GPI
anchors (e.g., porcine membrane dipeptidase and hu-
man CD52-I [38,41]) suggests that lipid remodelling
may also occur in some mammalian tissues. The
trypanosome VSG GPI anchors contain exclusively
myristic (C14:0) acid in the form of dimyristoylglycer-
ol [10] and lipid remodelling of GPI anchors was ¢rst
described in this organism [109]. The GPI intermedi-
ates in T. brucei are based on sn-1-stearoyl-2-acyl-PI
(where the acyl group at the sn-2 position is a mix-
ture [110]) up until the fatty acid remodelling steps
when the fatty acids are sequentially removed and
replaced by myristate (Fig. 3A). The trypanosome
also performs proofreading myristate exchange reac-
tions on the GPI precursor [111] and on the VSG-
linked mature GPI anchor [112] to ensure the exclu-
sivity of dimyristoylglycerol in the VSG anchor. This
type of myristate-speci¢c fatty acid remodelling has
been reported in Leishmania GPIs, where longer
chain fatty acids in the sn-2 position of sn-1-alkyl-
2-acyl-PI are replaced by myristate [81], but not in
mammalian cells. The need for myristate in the VSG
anchor remains obscure but myristate analogues that
become incorporated into the VSG anchor are toxic
to trypanosomes [113,114]. Thus, the enzymes of
fatty acid remodelling/myristate exchange and the
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other trypanosome systems required for scavenging
myristate [115] are possible targets for anti-trypano-
some chemotherapy.
2.10. The GPI-transamidase complex
The transfer of the mature GPI precursor to pro-
tein involves a transamidation reaction whereby a
COOH-terminal GPI addition signal peptide (typi-
cally 17^35 amino acids in length) is directly replaced
by the formation of an amide linkage to the amino
group of the ethanolamine phosphate bridge
[116,117]. In yeast the transamidase is made of at
least two components encoded by the GAA1 and
GPI8 genes [118,119]. The latter gene, which has ho-
mology with some plant endopeptidases, is believed
to encode the catalytic subunit while data presented
by Kinoshita and colleagues (unpublished work) sug-
gest that GAA1 encodes a subunit that is involved in
recognising the site of GPI addition in the protein
precursor. Species-speci¢c di¡erences in GPI-trans-
amidase speci¢city have been noted from site-di-
rected mutagenesis studies at and around the trans-
amidation (g) site [116,120]. For example, Cys is a
poor g amino acid in yeast but an acceptable residue
in mammalian cells. The g+1 and g+2 residues (i.e.,
the amino terminal and subterminal residues of the
cleaved GPI signal peptide) are also important deter-
minants for GPI-transamidation and these, like the g
amino acid, are generally relatively small residues.
Interestingly, the g/g+1/g+2 triplet of T. brucei
class-1 VSGs does not function in COS cells, suggest-
ing that there may be exploitable di¡erences between
mammalian and parasite GPI-transamidases [121].
Proteins that fail to acquire a GPI anchor are re-
tarded in the ER [122] and degraded by a protea-
some-dependent pathway [123,124].
3. Perspectives
Considerable progress has been made on the bio-
chemistry and molecular biology of GPI biosynthe-
sis. Despite the overall conservation of GPI core
structure, signi¢cant di¡erences in the substrate spe-
ci¢cities of trypanosome and mammalian GPI bio-
synthetic enzymes have been demonstrated. Thus, the
GlcNAc-PI de-N-acetylase, the MT-I and MT-III
mannosyltransferases, the inositol acyltransferase,
the inositol deacylase, the trypanosome-speci¢c fatty
acid remodelling/exchange enzymes, the GPI-trans-
amidase and the trypanosome-speci¢c side chain ga-
lactosyltransferases are all potential therapeutic tar-
gets. The fact that parasite-speci¢c inhibitors are
beginning to emerge is encouraging but the cloning
of T. brucei (and other pathogen) GPI pathway genes
and structural information on GPI pathway compo-
nents remain important goals for the future. Finally,
many other protozoan parasites, such as T. cruzi,
Leishmania, Plasmodium and Toxoplasma, are rich
in GPI-anchored glycoproteins and/or GPI-related
glycoconjugates. Therefore, GPI pathway inhibitors
developed with African trypanosomes may also have
therapeutic potential in a number of other diseases.
Acknowledgements
The authors’ work is supported by a Programme
Grant (054491) from The Wellcome Trust.
References
[1] K. Vickerman, A.G. Luckins, Nature 224 (1969) 1125^1126.
[2] G.A. Cross, Parasitology 71 (1975) 393^417.
[3] M.L. Blum, J.A. Down, A.M. Gurnett, M. Carrington, M.J.
Turner, D.C. Wiley, Nature 362 (1993) 603^609.
[4] G.A. Cross, Bioessays 18 (1996) 283^291.
[5] S.E. Zamze, E.W. Wooten, D.A. Ashford, M.A. Ferguson,
R.A. Dwek, T.W. Rademacher, Eur. J. Biochem. 187 (1990)
657^663.
[6] S.E. Zamze, D.A. Ashford, E.W. Wooten, T.W. Rademach-
er, R.A. Dwek, J. Biol. Chem. 266 (1991) 20244^20261.
[7] A. Mehlert, N. Zitzmann, J.M. Richardson, A. Treumann,
M.A. Ferguson, Mol. Biochem. Parasitol. 91 (1998) 145^
152.
[8] A.F. Williams, Immunol. Ser. 45 (1989) 49^69.
[9] M. Tarutani, S. Itami, M. Okabe, M. Ikawa, T. Tezuka, K.
Yoshikawa, T. Kinoshita, J. Takeda, Proc. Natl. Acad. Sci.
USA 94 (1997) 7400^7405.
[10] M.A. Ferguson, S.W. Homans, R.A. Dwek, T.W. Rade-
macher, Science 239 (1988) 753^759.
[11] A. Mehlert, J.M. Richardson, M.A. Ferguson, J. Mol. Biol.
277 (1998) 379^392.
[12] P. Gerold, B. Striepen, B. Reitter, H. Geyer, R. Geyer, E.
Reinwald, H.J. Risse, R.T. Schwarz, J. Mol. Biol. 261 (1996)
181^194.
[13] A. Treumann, N. Zitzmann, A. Hulsmeier, A.R. Prescott, A.
BBADIS 61863 15-9-99
M.A.J. Ferguson et al. / Biochimica et Biophysica Acta 1455 (1999) 327^340 337
Almond, J. Sheehan, M.A. Ferguson, J. Mol. Biol. 269
(1997) 529^547.
[14] P. Butikofer, M. Boschung, Mol. Biochem. Parasitol. 74
(1995) 65^75.
[15] M.L. Guther, M.L. de Almeida, N. Yoshida, M.A. Fergu-
son, J. Biol. Chem. 267 (1992) 6820^6828.
[16] N. Heise, M.L. de Almeida, M.A. Ferguson, Mol. Biochem.
Parasitol. 70 (1995) 71^84.
[17] L.E. Bertello, N.W. Andrews, R.M. de Lederkremer, Mol.
Biochem. Parasitol. 79 (1996) 143^151.
[18] A.S. Couto, R.M. De Lederkremer, W. Colli, M.J. Alves,
Eur. J. Biochem. 217 (1993) 597^602.
[19] G. Abuin, A.S. Couto, R.M. de Lederkremer, O.L. Casal, C.
Galli, W. Colli, M.J. Alves, Exp. Parasitol. 82 (1996) 290^
297.
[20] J.O. Previato, C. Jones, M.T. Xavier, R. Wait, L.R. Tra-
vassos, A.J. Parodi, L. Mendonca-Previato, J. Biol. Chem.
270 (1995) 7241^7250.
[21] A.A. Serrano, S. Schenkman, N. Yoshida, A. Mehlert, J.M.
Richardson, M.A. Ferguson, J. Biol. Chem. 270 (1995)
27244^27253.
[22] R. Agusti, A.S. Couto, O. Campetella, A.C. Frasch, R.M.
Lederkremer, Mol. Biochem. Parasitol. 97 (1998) 123^131.
[23] P. Schneider, M.A. Ferguson, M.J. McConville, A. Mehlert,
S.W. Homans, C. Bordier, J. Biol. Chem. 265 (1990) 16955^
16964.
[24] M.J. McConville, T.A. Collidge, M.A. Ferguson, P.
Schneider, J. Biol. Chem. 268 (1993) 15595^15604.
[25] S. Tomavo, J.F. Dubremetz, R.T. Schwarz, Biol. Cell 78
(1993) 155^162.
[26] P. Gerold, L. Scho¢eld, M.J. Blackman, A.A. Holder, R.T.
Schwarz, Mol. Biochem. Parasitol. 75 (1996) 131^143.
[27] N. Azzouz, B. Striepen, P. Gerold, Y. Capdeville, R.T.
Schwarz, EMBO J. 14 (1995) 4422^4433.
[28] C. Fankhauser, S.W. Homans, J.E. Thomas-Oates, M.J.
McConville, C. Desponds, A. Conzelmann, M.A. Ferguson,
J. Biol. Chem. 268 (1993) 26365^26374.
[29] P.A. Haynes, A.A. Gooley, M.A. Ferguson, J.W. Redmond,
K.L. Williams, Eur. J. Biochem. 216 (1993) 729^737.
[30] P. Butikofer, F.A. Kuypers, C. Shackleton, U. Brodbeck, S.
Stieger, J. Biol. Chem. 265 (1990) 18983^18987.
[31] A. Mehlert, L. Varon, I. Silman, S.W. Homans, M.A. Fer-
guson, Biochem. J. 296 (1993) 473^479.
[32] S.W. Homans, M.A. Ferguson, R.A. Dwek, T.W. Rade-
macher, R. Anand, A.F. Williams, Nature 333 (1988) 269^
272.
[33] N. Stahl, M.A. Baldwin, D.B. Teplow, L. Hood, B.W. Gib-
son, A.L. Burlingame, S.B. Prusiner, Biochemistry 32 (1993)
1991^2002.
[34] R. Mukasa, M. Umeda, T. Endo, A. Kobata, K. Inoue,
Arch. Biochem. Biophys. 318 (1995) 182^190.
[35] R. Taguchi, N. Hamakawa, M. Harada-Nishida, T. Fukui,
K. Nojima, H. Ikezawa, Biochemistry 33 (1994) 1017^
1022.
[36] R. Haas, B.C. Jackson, B. Reinhold, J.D. Foster, T.L.
Rosenberry, Biochem. J. 314 (1996) 817^825.
[37] J. Armesto, E. Hannappel, K. Leopold, W. Fischer, R. Bu-
blitz, L. Langer, G.A. Cumme, A. Horn, Eur. J. Biochem.
238 (1996) 259^269.
[38] I.A. Brewis, M.A. Ferguson, A. Mehlert, A.J. Turner, N.M.
Hooper, J. Biol. Chem. 270 (1995) 22946^22956.
[39] M.A. Deeg, D.R. Humphrey, S.H. Yang, T.R. Ferguson,
V.N. Reinhold, T.L. Rosenberry, J. Biol. Chem. 267 (1992)
18573^18580.
[40] C.A. Redman, J.E. Thomas-Oates, S. Ogata, Y. Ikehara,
M.A. Ferguson, Biochem. J. 302 (1994) 861^865.
[41] A. Treumann, M.R. Lifely, P. Schneider, M.A. Ferguson,
J. Biol. Chem. 270 (1995) 6088^6099.
[42] Y. Nakano, K. Noda, T. Endo, A. Kobata, M. Tomita,
Arch. Biochem. Biophys. 311 (1994) 117^126.
[43] Y. Sugita, Y. Nakano, E. Oda, K. Noda, T. Tobe, N.H.
Miura, M. Tomita, J. Biochem. 114 (1993) 473^477.
[44] S. Meri, T. Lehto, C.W. Sutton, J. Tyynela, M. Baumann,
Biochem. J. 316 (1996) 923^935.
[45] P.M. Rudd, B.P. Morgan, M.R. Wormald, D.J. Harvey,
C.W. van den Berg, S.J. Davis, M.A. Ferguson, R.A.
Dwek, J. Biol. Chem. 272 (1997) 7229^7244.
[46] J.L. Krakow, T.L. Doering, W.J. Masterson, G.W. Hart,
P.T. Englund, Mol. Biochem. Parasitol. 36 (1989) 263^270.
[47] S. Mayor, A.K. Menon, G.A. Cross, M.A. Ferguson, R.A.
Dwek, T.W. Rademacher, J. Biol. Chem. 265 (1990) 6164^
6173.
[48] S. Mayor, A.K. Menon, G.A. Cross, J. Biol. Chem. 265
(1990) 6174^6181.
[49] W.J. Masterson, T.L. Doering, G.W. Hart, P.T. Englund,
Cell 56 (1989) 793^800.
[50] S. Hirose, G.M. Prince, D. Sevlever, L. Ravi, T.L. Rose-
nberry, E. Ueda, M.E. Medof, J. Biol. Chem. 267 (1992)
16968^16974.
[51] A. Puoti, A. Conzelmann, J. Biol. Chem. 268 (1993) 7215^
7224.
[52] L.C. Costello, P. Orlean, J. Biol. Chem. 267 (1992) 8599^
8603.
[53] E. Canivenc-Gansel, I. Imhof, F. Reggiori, P. Burda, A.
Conzelmann, A. Benachour, Glycobiology 8 (1998) 761^770.
[54] C. Sutterlin, M.V. Escribano, P. Gerold, Y. Maeda, M.J.
Mazon, T. Kinoshita, R.T. Schwarz, H. Riezman, Biochem.
J. 332 (1998) 153^159.
[55] M.L. Guther, M.A. Ferguson, EMBO J. 14 (1995) 3080^
3093.
[56] T.L. Doering, W.J. Masterson, P.T. Englund, G.W. Hart,
J. Biol. Chem. 264 (1989) 11168^11173.
[57] S. Hirose, L. Ravi, S.V. Hazra, M.E. Medof, Proc. Natl.
Acad. Sci. USA 88 (1991) 3762^3766.
[58] J. Vidugiriene, A.K. Menon, J. Cell Biol. 121 (1993) 987^
996.
[59] J. Vidugiriene, A.K. Menon, J. Cell Biol. 127 (1994) 333^
341.
[60] R. Watanabe, T. Kinoshita, R. Masaki, A. Yamamoto, J.
Takeda, N. Inoue, J. Biol. Chem. 271 (1996) 26868^26875.
[61] R. Watanabe, N. Inoue, B. Westfall, C.H. Taron, P. Orlean,
J. Takeda, T. Kinoshita, EMBO J. 17 (1998) 877^885.
BBADIS 61863 15-9-99
M.A.J. Ferguson et al. / Biochimica et Biophysica Acta 1455 (1999) 327^340338
[62] S.D. Leidich, Z. Kostova, R.R. Latek, L.C. Costello, D.A.
Drapp, W. Gray, J.S. Fassler, P. Orlean, J. Biol. Chem. 270
(1995) 13029^13035.
[63] S.D. Leidich, P. Orlean, J. Biol. Chem. 271 (1996) 27829^
27837.
[64] A. Tiede, J. Schubert, C. Nischan, I. Jensen, B. Westfall,
C.H. Taron, P. Orlean, R.E. Schmidt, Biochem. J. 334
(1998) 609^616.
[65] K.G. Milne, M.A. Ferguson, W.J. Masterson, Eur. J. Bio-
chem. 208 (1992) 309^314.
[66] T.K. Smith, S. Cottaz, J.S. Brimacombe, M.A.J. Ferguson,
J. Biol. Chem. 271 (1996) 6476^6482.
[67] D.K. Sharma, T.K. Smith, A. Crossman, J.S. Brimacombe,
M.A.J. Ferguson, Biochem. J. 328 (1997) 171^177.
[68] N. Nakamura, N. Inoue, R. Watanabe, M. Takahashi, J.
Takeda, V.L. Stevens, T. Kinoshita, J. Biol. Chem. 272
(1997) 15834^15840.
[69] K.G. Milne, R.A. Field, W.J. Masterson, S. Cottaz, J.S.
Brimacombe, M.A.J. Ferguson, J. Biol. Chem. 269 (1994)
16403^16408.
[70] S. Cottaz, J.S. Brimacombe, M.A.J. Ferguson, J. Chem. Soc.
Perkin Trans. 1 (1995) 1673^1678.
[71] D.K. Sharma, T.K. Smith, C.T. Weller, A. Crossman, J.S.
Brimacombe, M.A. Ferguson, Glycobiology 9 (1999) 415^
422.
[72] T.K. Smith, D.K. Sharma, A. Crossman, A. Dix, J.S. Bri-
macombe, M.A. Ferguson, EMBO J. 16 (1997) 6667^
6675.
[73] W.T. Doerrler, J. Ye, J.R. Falck, M.A. Lehrman, J. Biol.
Chem. 271 (1996) 27031^27038.
[74] A.K. Menon, S. Mayor, R.T. Schwarz, EMBO J. 9 (1990)
4249^4258.
[75] A. Crossman, J.S. Brimacombe, M.A.J. Ferguson, J. Chem.
Soc. Perkin Trans. 1 (1997) 2769^2774.
[76] T.K. Smith, D.K. Sharma, A. Crossman, J.S. Brimacombe,
M.A.J. Ferguson, (1999) submitted.
[77] W.L. Roberts, B.H. Kim, T.L. Rosenberry, Proc. Natl.
Acad. Sci. USA 84 (1987) 7817^7821.
[78] W.L. Roberts, S. Santikarn, V.N. Reinhold, T.L. Rose-
nberry, J. Biol. Chem. 263 (1988) 18776^18784.
[79] D. Sevlever, D.R. Humphrey, T.L. Rosenberry, Eur. J. Bio-
chem. 233 (1995) 384^394.
[80] T.K. Smith, F.C. Milne, D.K. Sharma, A. Crossman, J.S.
Brimacombe, M.A. Ferguson, Biochem. J. 326 (1997) 393^
400.
[81] J.E. Ralton, M.J. McConville, J. Biol. Chem. 273 (1998)
4245^4257.
[82] G. Sipos, A. Puoti, A. Conzelmann, EMBO J. 13 (1994)
2789^2796.
[83] R. Chen, E.I. Walter, G. Parker, J.P. Lapurga, J.L. Millan,
Y. Ikehara, S. Udenfriend, M.E. Medof, Proc. Natl. Acad.
Sci. USA 95 (1998) 9512^9517.
[84] V.L. Stevens, H. Zhang, J. Biol. Chem. 269 (1994) 31397^
31403.
[85] M.L. Guther, W.J. Masterson, M.A. Ferguson, J. Biol.
Chem. 269 (1994) 18694^18701.
[86] M.L. Guther, A. Treumann, M.A. Ferguson, Mol. Bio-
chem. Parasitol. 77 (1996) 137^145.
[87] M. Takahashi, N. Inoue, K. Ohishi, Y. Maeda, N. Naka-
mura, Y. Endo, T. Fujita, J. Takeda, T. Kinoshita, EMBO
J. 15 (1996) 4254^4261.
[88] N. Dan, M.A. Lehrman, J. Biol. Chem. 272 (1997) 14214^
14219.
[89] J.R. Brown, M.L. Guther, R.A. Field, M.A. Ferguson,
Glycobiology 7 (1997) 549^558.
[90] M.P. Lisanti, M.C. Field, I.W. Caras, A.K. Menon, E.
Rodriguez-Boulan, EMBO J. 10 (1991) 1969^1977.
[91] Y.T. Pan, T. Kamitani, C. Bhuvaneswaran, Y. Hallaq,
C.D. Warren, E.T. Yeh, A.D. Elbein, J. Biol. Chem. 267
(1992) 21250^21255.
[92] J.E. Ralton, K.G. Milne, M.L. Guther, R.A. Field, M.A.
Ferguson, J. Biol. Chem. 268 (1993) 24183^24189.
[93] W.J. Masterson, M.A. Ferguson, EMBO J. 10 (1991) 2041^
2045.
[94] A.K. Menon, V.L. Stevens, J. Biol. Chem. 267 (1992)
15277^15280.
[95] A.K. Menon, M. Eppinger, S. Mayor, R.T. Schwarz,
EMBO J. 12 (1993) 1907^1914.
[96] N. Inoue, T. Kinoshita, T. Orii, J. Takeda, J. Biol. Chem.
268 (1993) 6882^6885.
[97] C. Sutterlin, A. Horvath, P. Gerold, R.T. Schwarz, Y.
Wang, M. Dreyfuss, H. Riezman, EMBO J. 16 (1997)
6374^6383.
[98] G. Sipos, A. Puoti, A. Conzelmann, J. Biol. Chem. 270
(1995) 19709^19715.
[99] S. Pingel, R.A. Field, M.L. Guther, M. Duszenko, M.A.
Ferguson, Biochem. J. 309 (1995) 877^882.
[100] T. Ziegler, R. Dettmann, M. Duszenko, V. Kolb, Carbo-
hydr. Res. 295 (1996) 7^23.
[101] J.R. Brown, T.K. Smith, M.A.J. Ferguson, R.A. Field, Bio-
org. Med. Chem. Lett. 8 (1998) 2051^2054.
[102] S. Mayor, A.K. Menon, G.A. Cross, J. Biol. Chem. 267
(1992) 754^761.
[103] J.D. Bangs, T.L. Doering, P.T. Englund, G.W. Hart,
J. Biol. Chem. 263 (1988) 17697^17705.
[104] M. Carrington, N. Miller, M. Blum, I. Roditi, D. Wiley, M.
Turner, J. Mol. Biol. 221 (1991) 823^835.
[105] M.L. Guther, M.A. Ferguson, Methods Mol. Biol. 14
(1993) 99^117.
[106] S.W. Homans, C.J. Edge, M.A. Ferguson, R.A. Dwek,
T.W. Rademacher, Biochemistry 28 (1989) 2881^2887.
[107] F. Reggiori, E. Canivenc-Gansel, A. Conzelmann, EMBO
J. 16 (1997) 3506^3518.
[108] F. Reggiori, A. Conzelmann, J. Biol. Chem. 273 (1998)
30550^30559.
[109] W.J. Masterson, J. Raper, T.L. Doering, G.W. Hart, P.T.
Englund, Cell 62 (1990) 73^80.
[110] T.L. Doering, M.S. Pessin, G.W. Hart, D.M. Raben, P.T.
Englund, Biochem. J. 299 (1994) 741^746.
[111] L.U. Buxbaum, J. Raper, F.R. Opperdoes, P.T. Englund,
J. Biol. Chem. 269 (1994) 30212^30220.
BBADIS 61863 15-9-99
M.A.J. Ferguson et al. / Biochimica et Biophysica Acta 1455 (1999) 327^340 339
[112] L.U. Buxbaum, K.G. Milne, K.A. Werbovetz, P.T. En-
glund, Proc. Natl. Acad. Sci. USA 93 (1996) 1178^1183.
[113] T.L. Doering, T. Lu, K.A. Werbovetz, G.W. Gokel, G.W.
Hart, J.I. Gordon, P.T. Englund, Proc. Natl. Acad. Sci.
USA 91 (1994) 9735^9739.
[114] T.L. Doering, J. Raper, L.U. Buxbaum, S.P. Adams, J.I.
Gordon, G.W. Hart, P.T. Englund, Science 252 (1991)
1851^1854.
[115] K.A. Werbovetz, P.T. Englund, Mol. Biochem. Parasitol.
85 (1997) 1^7.
[116] K. Kodukula, S.E. Maxwell, S. Udenfriend, Methods En-
zymol. 250 (1995) 536^547.
[117] S. Ramalingam, S.E. Maxwell, M.E. Medof, R. Chen, L.D.
Gerber, S. Udenfriend, Proc. Natl. Acad. Sci. USA 93
(1996) 7528^7533.
[118] D. Hamburger, M. Egerton, H. Riezman, J. Cell Biol. 129
(1995) 629^639.
[119] M. Benghezal, A. Benachour, S. Rusconi, M. Aebi, A.
Conzelmann, EMBO J. 15 (1996) 6575^6583.
[120] C. Nuo¡er, P. Jeno, A. Conzelmann, H. Riezman, Mol.
Cell. Biol. 11 (1991) 27^37.
[121] P. Moran, I.W. Caras, J. Cell Biol. 125 (1994) 333^343.
[122] M.C. Field, P. Moran, W. Li, G.A. Keller, I.W. Caras,
J. Biol. Chem. 269 (1994) 10830^10837.
[123] K. Oda, Y. Ikehara, S. Omura, Biochem. Biophys. Res.
Commun. 219 (1996) 800^805.
[124] B. Wilbourn, D.N. Nesbeth, L.J. Wainwright, M.C. Field,
Biochem. J. 332 (1998) 111^118.
BBADIS 61863 15-9-99
M.A.J. Ferguson et al. / Biochimica et Biophysica Acta 1455 (1999) 327^340340
